Zydus and Lupin Join Forces to Revolutionize Diabetes Care in India

Zydus Lifesciences and Lupin have announced a significant licensing agreement to market Semaglutide Injection in India, aiming to enhance advanced diabetes and weight management therapies. The collaboration focuses on improving patient access and treatment convenience with a reusable pen device, fortifying their commitment to innovative healthcare solutions in India.

Zydus Lifesciences has teamed up with Lupin in a landmark agreement to make diabetes treatment more accessible in India. The two companies will market Semaglutide Injection using an innovative reusable pen device.

Under the terms of the deal, Zydus will market the drug under brand names such as Semaglyn, while Lupin will market it as Semanext and Livarise. Lupin's rights allow them to co-market the semaglutide injection, underscoring a commitment to provide advanced treatment for cardio-metabolic diseases.

Zydus Lifesciences MD Sharvil Patel highlighted the pact's patient-centric approach, and Lupin MD Nilesh Gupta stated the partnership aims to enhance diabetes care and expand high-quality treatment options throughout India.

(With inputs from agencies.)